Browsing: Obesity & Weight Management

Summary: In patients undergoing laparoscopic sleeve gastrectomy (LSG), a combination of preoperative HDL-C and visceral adipose tissue (VAT) significantly predicted…

A SURMOUNT-1 analysis finds tirzepatide improves insulin sensitivity (mostly via weight loss) and beta-cell function (mostly drug-driven) in obesity without diabetes. PICO summary and commentary.

A SURMOUNT-1 analysis finds 90% of early non-responders to tirzepatide still reached 5% weight loss by week 72, supporting extending treatment. PICO summary and commentary.

Summary: In individuals with type 2 diabetes, cinnamon supplementation significantly reduced  anthropometric measurements compared to placebo, though it was not…

“`html Summary: In patients with type 2 diabetes mellitus, a combined exercise program significantly reduced abdominal fat and improved sleep…

Summary: In patients with type 2 diabetes mellitus (T2DM), Ebenatide treatment significantly improved glycemic control (HbA1c, TIR, TyG), reduced body…

First-in-human phase 1 trial finds the oral GLP-1/amylin co-agonist amycretin safe and well tolerated with dose-dependent gastrointestinal effects; weight and glucose changes were exploratory only. PICO summary and expert commentary.

An early-phase trial reports large but exploratory weight-loss signals for subcutaneous amycretin in overweight and obesity, with safety as the primary focus. PICO summary and expert commentary.

An Eli Lilly-sponsored indirect treatment comparison links tirzepatide 10 and 15 mg to greater weight, BMI and HbA1c reductions than semaglutide 2.4 mg in patients with type 2 diabetes, with no head-to-head trial. PICO summary and expert commentary.

A phase 2b trial finds oral danuglipron produces significant weight loss in obesity but with high discontinuation from gastrointestinal side effects. PICO summary and commentary.